Drug class
Hydrolytic Lysosomal N-terminal Tripeptidyl Peptidase
Mechanism of action
CLN2 disease is a neurodegenerative disease caused by deficiency of the lysosomal enzyme tripeptidyl peptidase-1 (TPP1), which catabolizes polypeptides in the CNS.
General use cases
- Neuronal Ceroid-Lipofuscinoses
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
